News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Evaluate the safety and efficacy, as determined by 90-day incidence of mortality or transplant, for intravenous (IV) DUR-928 (30 mg or 90 mg) in subjects with severe alcohol-associated hepatitis, also known as severe alcoholic hepatitis, (AH) with pre-treatment Maddrey Discriminant Function (MDF) score ≥ 32 and MELD scores 21-30

Study Status:

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To evaluate the effect of EFX compared to placebo on fibrosisregression in subjects with compensated cirrhosis due to NASH at Week 36

Information: 

Principal Investigator
Fernando Membreno, MD
Sponsor
Akero Therapeutics, Inc.
Type of Trial
Interventional
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram